AR041786A1 - Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento - Google Patents

Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento

Info

Publication number
AR041786A1
AR041786A1 ARP030100876A ARP030100876A AR041786A1 AR 041786 A1 AR041786 A1 AR 041786A1 AR P030100876 A ARP030100876 A AR P030100876A AR P030100876 A ARP030100876 A AR P030100876A AR 041786 A1 AR041786 A1 AR 041786A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
derivatives
phenyl
preparation
Prior art date
Application number
ARP030100876A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206218A external-priority patent/GB0206218D0/en
Priority claimed from GB0229627A external-priority patent/GB0229627D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR041786A1 publication Critical patent/AR041786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Derivados de azetidina como antagonistas del receptor CCR-3 según la fórmula (1) en forma de sal o libre, donde Ar es un fenilo opcionalmente substituido por uno o más substitutos seleccionados a partir de halógeno, C1-8-alquilo, ciano o nitro; R1 es hidrógeno, o C1-8-alquilo, opcionalmente substituido por hidroxi, C1-8-alquilo, aciloxi, halógeno, carboxi, C1-8-alcoxicarbonilo, -N(R4)R5, -CON(R6)R7 o por un grupo orgánico cíclico monovalente que tiene de 3 a 15 átomos en el sistema de anillo; R2 es hidrógeno, C1-8-alquilo, o C3-10-cicloalquilo, y R3 es C1-8-alquilo substituido por fenilo, fenoxi, alcoxi o naftilo, o R3 es C3-10-cicloalquilo que tiene opcionalmente un grupo benzo fusionado al mismo, un grupo heterocíclico que tiene 5 a 10 átomos de anillo de los cuales 1 a 4 son heteroátomos, fenilo o naftilo, substituyéndose opcionalmente dichos grupos fenilo, fenoxi o naftilo por uno o más substituidos seleccionados a partir de halógeno, ciano, hidroxi, acilo, nitro, -SO2NH2, C1-8-alquilo opcionalmente substituido por C1-8-alcoxi, C1-8-haloalquilo, C1-8-alcoxi, C1-8-haloalcoxi, C1-8-alquiltio, SO2-C1-8-alquilo, C1-8-alcoxicarbonilo, C1-8-acilamino opcionalmente substituidos en el átomo de nitrógeno por C1-8-alquilo, C1-8-alquilamino, aminocarbonilo, C1-8-alquilamino-carbonilo, di(C1-8-alquil)amino, di(C1-8-alquil)aminocarbonilo, di(C1-8-alquil)aminocarbonil-metoxi, o o R2 o R3 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico que tiene de 5 a 10 átomos de anillo de los cuales 1, 2 o 3 son heteroátomos; R4 y R5 son cada uno independientemente hidrógeno o C1-8-alquilo, o R4 es hidrógeno y R5 es hidroxi-C1-8-alquilo, acilo, -SO2R8 o -CON(R6)R7, o R4 y R5 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros; R6 y R7 son cada uno independientemente hidrógeno o C1-8-alquilo, o R6 y R7 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros; R8 es C1-8-alquilo, C1-8-haloalquilo, o fenilo opcionalmente substituido por C1-8-alquilo; X es -C(=O)-, -O-, -CH2-, o CH(OH); Y es oxígeno o azufre; m es 1, 2, 3 o 4; y n, p y q son cada uno 0 o 1, n+p+q=1, y cuando n es 0, p es 0, son útiles para tratar condiciones mediadas por CCR3. También se describen las composiciones farmacéuticas que contienen los compuestos y procesos para preparar los compuestos y el uso de dichos derivados para la elaboración de un medicamento.
ARP030100876A 2002-03-15 2003-03-13 Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento AR041786A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0206218A GB0206218D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0229627A GB0229627D0 (en) 2002-12-19 2002-12-19 Organic compounds

Publications (1)

Publication Number Publication Date
AR041786A1 true AR041786A1 (es) 2005-06-01

Family

ID=28043401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100876A AR041786A1 (es) 2002-03-15 2003-03-13 Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento

Country Status (18)

Country Link
US (1) US7288537B2 (es)
EP (1) EP1487435A1 (es)
JP (2) JP4332433B2 (es)
KR (1) KR100706270B1 (es)
CN (1) CN1638761A (es)
AR (1) AR041786A1 (es)
AU (1) AU2003227072B2 (es)
BR (1) BR0308419A (es)
CA (1) CA2479266A1 (es)
CO (1) CO5611125A2 (es)
IL (1) IL164016A0 (es)
MX (1) MXPA04009057A (es)
NO (1) NO20044373L (es)
NZ (1) NZ535082A (es)
PL (1) PL371055A1 (es)
RU (1) RU2314292C2 (es)
TW (2) TW200800167A (es)
WO (1) WO2003077907A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2007505080A (ja) * 2003-09-15 2007-03-08 ノバルティス アクチエンゲゼルシャフト 炎症性およびアレルギー性疾患の処置における、ｃｃｒ−３受容体アンタゴニストとして使用するための１，３−二置換アゼチジン誘導体
GB0402101D0 (en) 2004-01-30 2004-03-03 Novartis Ag Organic compounds
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
GB0417801D0 (en) 2004-08-10 2004-09-15 Novartis Ag Organic compounds
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0720390D0 (en) * 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) * 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
KR20200125932A (ko) 2018-01-26 2020-11-05 랩트 테라퓨틱스, 인크. 케모카인 수용체 조정제 및 그의 용도
CN110498750B (zh) * 2019-09-02 2021-10-15 南通大学 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2093456B (en) 1980-10-08 1984-12-05 Robins Co Inc A H 1-r1-3-phenozyazetidines
US5095014A (en) * 1990-12-07 1992-03-10 A. H. Robins Company, Incorporated 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
GB0117387D0 (en) * 2001-07-17 2001-09-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR100706270B1 (ko) 2007-04-11
US20050222118A1 (en) 2005-10-06
RU2314292C2 (ru) 2008-01-10
IL164016A0 (en) 2005-12-18
KR20040091690A (ko) 2004-10-28
CN1638761A (zh) 2005-07-13
JP2009102325A (ja) 2009-05-14
NZ535082A (en) 2006-08-31
TW200305395A (en) 2003-11-01
JP2005526773A (ja) 2005-09-08
WO2003077907A1 (en) 2003-09-25
US7288537B2 (en) 2007-10-30
RU2004130487A (ru) 2005-07-10
AU2003227072A1 (en) 2003-09-29
MXPA04009057A (es) 2005-01-25
CA2479266A1 (en) 2003-09-25
NO20044373L (no) 2004-10-14
CO5611125A2 (es) 2006-02-28
EP1487435A1 (en) 2004-12-22
BR0308419A (pt) 2005-01-18
AU2003227072B2 (en) 2006-08-10
PL371055A1 (en) 2005-06-13
TW200800167A (en) 2008-01-01
JP4332433B2 (ja) 2009-09-16

Similar Documents

Publication Publication Date Title
AR041786A1 (es) Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
AR028531A1 (es) Compuestos organicos
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
TW200633979A (en) Method
AR041724A1 (es) Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
CO5261559A1 (es) Antagonistas de neurokinina selectivos
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
AR035548A1 (es) Compuestos organicos
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR040412A1 (es) Derivados de sulfamato sustituido como anticonvulsivo
ES2127919T3 (es) 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos.
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
ECSP045073A (es) Nuevos derivados de piperazina
PE20001303A1 (es) Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
CO5540385A2 (es) Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
PE20090548A1 (es) Compuestos aza-biciclohexano como inhibidores de trombina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal